Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Apraglutide

Repair & Recovery

Molecular Dossier

  • Rank Index: 49
  • Status: Phase 2 Clinical
  • What does this mean?
  • Molecular Structure: MW: ~3,752 Da | 33 AA GLP-2 sequence | Oral formulation variant

About Apraglutide

Apraglutide is an oral GLP-2 agonist in Phase 2 development for short bowel syndrome (SBS) and other intestinal mucosal disorders. GLP-2 (glucagon-like peptide-2) is an endogenous intestinotrophic hormone that stimulates intestinal epithelial proliferation, increases blood flow to the mucosa, and reduces intestinal permeability. Parenteral GLP-2 analogues (teduglutide/Gattex) are FDA-approved for SBS but require daily injection. Apraglutide employs oral formulation technology to achieve bioavailability despite the peptidic structure. Phase 2 trials (2025–2026) are evaluating efficacy in SBS and Crohn's disease-related intestinal inflammation. Once-daily oral dosing. The intestinal repair mechanism is distinct from systemic metabolic peptides and may offer therapeutic benefit in IBS, celiac disease, and post-surgical gut dysfunction. Long-term safety data are limited to Phase 2; Phase 3 trials expected 2026–2027.

Clinical Focus

Oral GLP-2 Agonist — Intestinal Mucosal Repair & Gut Barrier

Archival Aliases

Oral GLP-2, Apraglutide ALG-010001

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: ~3,752 Da | 33 AA GLP-2 sequence | Oral formulation variant
Primary Pathway Repair & Recovery
Research Phase Phase 2 Clinical

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] clinicaltrials.gov
[REF 2] pubmed.ncbi.nlm.nih.gov

Data Verified: 2026-05-07

Synergistic Matrix